MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
DENTSPLY SIRONA Operating Income 2011-2025 | XRAY
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income DENTSPLY SIRONA
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -879 M | -85 M | -937 M | 608 M | -3 M | 353 M | -958 M | -1.56 B | 455 M | 375 M | 446 M | 419 M | 382 M | 301 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 608 M | -1.56 B | -77.6 M |
Quarterly Operating Income DENTSPLY SIRONA
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -218 M | -128 M | 63 M | - | -462 M | 50 M | 42 M | - | -236 M | 80 M | -2 M | - | -1.22 B | 119 M | 97 M | - | 132 M | 154 M | 150 M | - | 82 M | -104 M | -125 M | 137 M | 110 M | 67.5 M | 47.3 M | 81.8 M | 45.5 M | -1.15 B | 68.7 M | -706 M | 108 M | -1.05 B | 84.2 M | 134 M | 127 M | 121 M | 72.7 M | 93.1 M | 98.6 M | 85.8 M | 97.7 M | 103 M | 110 M | 127 M | 106 M | 97.4 M | 105 M | 123 M | 93.9 M | - | 88.7 M | 109 M | 87.2 M | - | 39.8 M | 97 M | 98.6 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 154 M | -1.22 B | -28.2 M |
Operating Income of other stocks in the Medical instruments industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Baxter International
BAX
|
14 M | $ 19.11 | 0.95 % | $ 9.75 B |  USA |
 |
Becton, Dickinson and Company
BDX
|
2.58 B | $ 196.12 | 0.23 % | $ 56.4 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
-10.5 M | $ 5.47 | 3.01 % | $ 110 M | USA |
 |
iRhythm Technologies
IRTC
|
-116 M | $ 175.8 | -1.49 % | $ 5.48 B | USA |
 |
Isoray
ISR
|
-90.9 M | - | 0.03 % | $ 108 M | USA |
 |
Repro Med Systems
KRMD
|
-10.3 M | $ 6.48 | -0.61 % | $ 295 M | USA |
 |
Harvard Bioscience
HBIO
|
1.89 M | $ 0.73 | 0.64 % | $ 31 M | USA |
 |
LeMaitre Vascular
LMAT
|
52.3 M | $ 84.34 | 0.44 % | $ 1.89 B | USA |
 |
ICU Medical
ICUI
|
43 M | $ 146.98 | -0.35 % | $ 3.58 B | USA |
 |
Alcon
ALC
|
580 M | $ 80.17 | 0.06 % | $ 40.4 B |  Schweiz |
 |
Merit Medical Systems
MMSI
|
156 M | $ 87.39 | -0.27 % | $ 5.09 B | USA |
 |
AtriCure
ATRC
|
-40 M | $ 40.55 | 0.02 % | $ 1.9 B | USA |
 |
Atrion Corporation
ATRI
|
22.6 K | - | - | $ 810 M | USA |
 |
electroCore
ECOR
|
-19.3 M | $ 4.86 | 1.25 % | $ 26.8 K | USA |
 |
AngioDynamics
ANGO
|
-40 M | $ 13.16 | - | $ 538 M | USA |
 |
The Cooper Companies
COO
|
683 M | $ 82.57 | -0.37 % | $ 16.4 B | USA |
 |
Glaukos Corporation
GKOS
|
-129 M | $ 116.64 | 0.4 % | $ 5.65 B | USA |
 |
Masimo Corporation
MASI
|
-267 M | $ 133.28 | -0.44 % | $ 7.1 B | USA |
 |
Haemonetics Corporation
HAE
|
222 M | $ 80.01 | -0.44 % | $ 4.03 B | USA |
 |
InfuSystem Holdings
INFU
|
1.65 M | $ 9.11 | 0.77 % | $ 188 M | USA |
 |
Predictive Oncology
POAI
|
-10.9 M | - | - | $ 32.4 M | USA |
 |
Intuitive Surgical
ISRG
|
2.35 B | $ 577.15 | -0.03 % | $ 205 B | USA |
 |
OraSure Technologies
OSUR
|
-28.2 M | $ 2.43 | 2.53 % | $ 181 M | USA |
 |
Microbot Medical
MBOT
|
-9.86 M | $ 2.18 | - | $ 22.2 M |  Israel |
 |
Milestone Scientific
MLSS
|
-6.76 M | $ 0.29 | -0.48 % | $ 23.1 M | USA |
 |
Nephros
NEPH
|
-1.59 M | $ 5.23 | 12.23 % | $ 54.3 M | USA |
 |
NeuroMetrix
NURO
|
-8.78 M | - | 5.05 % | $ 9.02 M | USA |
 |
Envista Holdings Corporation
NVST
|
-1.04 B | $ 22.0 | 0.59 % | $ 3.79 B | USA |
 |
Stereotaxis
STXS
|
-21.8 M | $ 2.43 | -0.82 % | $ 196 M | USA |
 |
Pro-Dex
PDEX
|
10.7 M | $ 40.4 | -2.38 % | $ 133 M | USA |
 |
Pulse Biosciences
PLSE
|
-43.6 M | $ 14.86 | 1.92 % | $ 714 M | USA |
 |
ResMed
RMD
|
1 B | $ 244.44 | -0.07 % | $ 35.7 B | USA |
 |
Repligen Corporation
RGEN
|
47.7 M | $ 165.66 | -0.42 % | $ 9.23 M | USA |
 |
BioLife Solutions
BLFS
|
-7.13 M | $ 25.41 | -0.2 % | $ 1.17 B | USA |
 |
STAAR Surgical Company
STAA
|
-12.6 M | $ 23.63 | -1.25 % | $ 1.16 B | USA |
 |
STERIS plc
STE
|
867 M | $ 255.68 | 0.11 % | $ 25.2 B | USA |
 |
Retractable Technologies
RVP
|
-21.1 M | $ 0.82 | 0.01 % | $ 24.5 M | USA |
 |
Teleflex Incorporated
TFX
|
151 M | $ 122.33 | 0.03 % | $ 5.73 B | USA |
 |
Utah Medical Products
UTMD
|
16.8 M | $ 56.29 | -1.14 % | $ 204 M | USA |
 |
West Pharmaceutical Services
WST
|
570 M | $ 276.66 | -0.3 % | $ 20.2 B | USA |